Paul Hudson, Getty Images
Sanofi shows off positive PhIII trial results for Toujeo, opening the door to a new group of diabetes patients
A little under two months since their latest setback in diabetes R&D as their dominant perch in the market is shaken by severe headwinds, Sanofi …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
